![The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women - Maturitas The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women - Maturitas](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/6a31de94-054e-41c7-9a6e-47a31db95507/gr1_lrg.jpg)
The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women - Maturitas
![Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance - Boonen - 2008 - Journal of Internal Medicine - Wiley Online Library Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance - Boonen - 2008 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/1842f350-07c7-4a5f-bad8-a94c0e86c3c5/joim_2010_t1.gif)
Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance - Boonen - 2008 - Journal of Internal Medicine - Wiley Online Library
![Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a9b7fbce-c7e7-4ce3-8324-1bc6e975115b/gr6_lrg.jpg)
Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
![Small molecule inhibitors of the Dishevelled‐CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy | EMBO Molecular Medicine Small molecule inhibitors of the Dishevelled‐CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/34e48f2e-5068-401a-be66-fe211a718d20/emmm201505714-fig-0007-m.jpg)
Small molecule inhibitors of the Dishevelled‐CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy | EMBO Molecular Medicine
![High C-Terminal Cross-Linking Telopeptide Levels Are Associated With a Minimal Risk of Osteonecrosis of the Jaws in Patients Taking Oral Bisphosphonates and Having Exodontia - Journal of Oral and Maxillofacial Surgery High C-Terminal Cross-Linking Telopeptide Levels Are Associated With a Minimal Risk of Osteonecrosis of the Jaws in Patients Taking Oral Bisphosphonates and Having Exodontia - Journal of Oral and Maxillofacial Surgery](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ccaed9e7-6533-493b-a326-7c7c672dddde/gr1_lrg.jpg)
High C-Terminal Cross-Linking Telopeptide Levels Are Associated With a Minimal Risk of Osteonecrosis of the Jaws in Patients Taking Oral Bisphosphonates and Having Exodontia - Journal of Oral and Maxillofacial Surgery
![References in Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial - The Lancet References in Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2110404489/2083174425/gr1.gif)
References in Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial - The Lancet
![Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data - The Lancet Oncology Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/6cffac70-7d63-4728-80f2-f31b1791932f/gr1.gif)
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data - The Lancet Oncology
![Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? - Kidney International Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? - Kidney International](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2043430681/2056027240/gr1.jpg)
Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? - Kidney International
![Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment - ScienceDirect Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2212440318311933-gr5.jpg)
Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment - ScienceDirect
![Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel - Journal of Thoracic Oncology Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2039813156/2053412031/gr1.jpg)